BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2 AND Treatment
7 results:

  • 1. Identification of genes associated with Kikuchi-Fujimoto disease using RNA and exome sequencing.
    Anuntakarun S; Larbcharoensub N; Payungporn S; Reamtong O
    Mol Cell Probes; 2021 Jun; 57():101728. PubMed ID: 33819568
    [TBL] [Abstract] [Full Text] [Related]  

  • 2.
    Heatley SL; Asari K; Schutz CE; Leclercq TM; McClure BJ; Eadie LN; Hughes TP; Yeung DT; White DL
    Leuk Lymphoma; 2021 May; 62(5):1157-1166. PubMed ID: 33390067
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Deleted in lymphocytic leukemia 1 promoted proliferation and apoptosis of nephroblastoma cells through regulating miR-513a-5p and ranbp2 pathway].
    Zhao JL; Zhao LL; Niu WZ; Ding XC; Zhang WL
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):849-855. PubMed ID: 33113626
    [No Abstract]    [Full Text] [Related]  

  • 4. CD30 and ALK combination therapy has high therapeutic potency in ranbp2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
    Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
    Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic Factors and Survival in Primary Central Nervous System lymphoma: A Population-Based Study.
    Shan Y; Hu Y
    Dis Markers; 2018; 2018():7860494. PubMed ID: 30050595
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (ranbp2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
    Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
    Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A case report of epithelioid inflammatory myofibroblastic sarcoma with ranbp2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.